Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.47 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.47 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.47 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.47 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.47 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.47 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.47 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 13/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400838 | 0.86 | DYRK1A (0.50) | FLT3 | |
| SCHEMBL5408800 | 0.85 | FLT3 (0.54) | FLT3TTK | |
| SCHEMBL3469554 | 0.84 | TTK (0.64) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL3467726 | 0.84 | TTK (0.57) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL5394653 | 0.84 | FLT3 (0.53) | FLT3TTK | |
| SCHEMBL5403960 | 0.82 | FLT3 (0.56) | FLT3TTK | |
| SCHEMBL5403916 | 0.81 | FLT3 (0.51) | FLT3TTK | |
| SCHEMBL5416156 | 0.80 | FLT3 (0.54) | FLT3TTK | |
| SCHEMBL5411618 | 0.79 | FLT3 (0.56) | FLT3TTK | |
| SCHEMBL5401420 | 0.79 | FLT3 (0.56) | FLT3TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | claimed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157460-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | SUGEN, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | FLT3 216/4885ATP1A1 1963/4885ATP1B1 2157/4885 |
| US-20040220189-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhbitors | MAP3K8, MAP4K4, MAP3K2 | FLT3 215/4885ATP1A1 1459/4885ATP1B1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.